Clinical Trial Update: Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D) [Phase 2]

View source ↗

Summary

This trial update reports termination of the Phase 2 study of olorlinab for irritable bowel syndrome, including IBS with constipation and IBS with diarrhea, wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Irritable Bowel Syndrome
• Irritable Bowel Syndrome with Constipation
• Irritable Bowel Syndrome with Diarrhea

Drugs mentioned

• olorinab (olorinab)

Snippet

Sponsor: Arena Pharmaceuticals | Conditions: Irritable Bowel Syndrome | Phase 2 | Status: TERMINATED | Results posted: 2022-10-12